Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-To-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase 3 Randomized Controlled Trials
Provide enhanced digital features for this article
This Figshare page contains a Summary Slide. If you are an author of this publication and
would like to provide additional enhanced digital features for your article
then please contact email@example.com.
The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.
Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides